Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

Human Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 267-274

  Adams, David H ^a   Close, Sandra ^a   Farmen, Mark ^a   Downing, Ann Catherine M ^a   Breier, Alan ^a   Houston, John P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Genetic association; Pharmacogenomics; Polymorphism; Response

Indexed keywords

DOPAMINE 3 RECEPTOR; GLYCINE; HALOPERIDOL; OLANZAPINE; SERINE;

ADULT; ALLELE; ANALYSIS OF VARIANCE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 47249116664     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.930     Document Type: Article

References (28)

1. Cavalli-Sforza LL, Bodmer WF. 1999. The Genetics Of Human Populations. Dover Publications: New York; 57.
2. Crocq MA, Mant R, Asherson P, et al. 1992. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 29: 858-860.
3. Crocq MA, Buguet A, Bisser S, et al. 1996. BaII and MspI polymorphisms of the dopamine D3 receptor gene in African Blacks and Caucasians. Hum Hered 46: 58-60.
4. Dubertret C, Gorwood P, Ades J, Feingold J, Schwartz JC, Sokoloff P. 1998. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 81: 318-322.
5. Excoffier L, Slatkin M. 1995. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12: 921-927.
6. Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies http://hydra.usc.edu/gxe.
7. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. 1997. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54: 225-232.
8. Hellstrand M, Danielsen EA, Steen VM, Ekman A, Eriksson E, Nilsson CL. 2004. The ser9gly SNP in the dopamine D3 receptor causes a shift from cAMP related to PGE2 related signal transduction mechanisms in transfected CHO cells. J Med Genet 41: 867-871.
9. International HapMap Project. HapMap Genotype Database http://www.hapmap.org.
10. Jonsson EG, Flyckt L, Burgert E, et al. 2003. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 13: 1-12.
11. Joyce JN, Millan MJ. 2005. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10: 917-925.
12. Jurinke C, van den Boom D, Cantor CR, Koster H. 2002. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 187: 179-192.
13. Kay SR, Opler LA, Fiszbein A. 1992. Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems: North Tonawanda, NY.
14. Lane HY, Hsu Sk, Liu YC, Chang YC, Huang CH, Chang WH. 2005. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 25: 6-11.
15. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirshhorn JN. 2003. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177-182.
16. Lundstrom K, Turpin MP. 1996. Proposed schizophrenia-related polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225: 1068-1072.
17. Mancama D, Arranz MJ, Kerwin RW. 2002. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 16: 317-324.
18. Millan MJ, Brocco M, Rivet JM, et al. 2000. S18327 (1-[2-[4-(6-fluoro-1,2-benxisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)- adrenergic receptors: II. Functional profile and a multiparametric comparson with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292: 54-66.
19. 1 receptor affinity than olanzapine. J Pharmacol Exp Ther 315: 1265-1277.
20. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. 2005. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15: 143-151.
21. Robertson GS, Lee CJ, Sridhar K, et al. 2004. Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 20: 3189-3194.
22. Scharfetter J, Chaudhry HR, Homik K, et al. 1999. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol 10: 17-20.
23. Shaikh S, Collier DA, Sham PC, et al. 1996. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 97: 714-719.
24. Staddon S, Arranz M J, Mancama D, Mata I, Kerwin RW. 2002. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 162: 18-23.
25. Szkeres G, Keri Z, Juhasz A, et al. 2004. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124: 1-5.
26. Tollefson GD, Beasley CM, Jr, Tran PV, et al. 1997. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-465.
27. Vogel M, Pfeifer S, Schaub RT, et al. 2004. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50: 305-310.
28. Williams J, Spurlock G, Holmans P, et al. 1998. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry 3: 141-149.